Dr. Deshpande joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President of Research and Development in October 2010. In May 2013, Dr. Deshpande was appointed President and Chief Executive Officer of Achillion and joined the Board of Directors. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his PhD in Organic Chemistry from Ohio University, following his undergraduate education in India.
Executive Vice President and Chief Financial Officer
Ms. Fenton, a certified public accountant, has led Achillion’s financial function since October 2000, and is responsible for financial strategy development and capital formation, financial reporting and compliance, treasury and tax functions, as well as operating functions including risk management, legal compliance, facilities management, purchasing, and information technology. From 1991 to 2000, Ms. Fenton held various positions within the Technology Industry Group at PricewaterhouseCoopers LLC, most recently as Senior Manager responsible for the life sciences practice in Connecticut. Prior to 1991, Ms. Fenton was an economic development associate in the nonprofit sector. Ms. Fenton holds an MBA in Finance from the Graduate School of Business at the University of Connecticut and an AB in Economics from the College of the Holy Cross.
Executive Vice President, General Counsel and Secretary
Martha E. Manning, Esq. joined Achillion in February 2016 as General Counsel. Previously, she was General Counsel of iCeutica Inc., a drug development company from 2013 to 2016. She served as Chief Legal Officer of OraPharma, Inc., a J&J spinout company, from 2011 to 2012 when the Company was acquired by Valeant. She joined OraPharma from Sandoz Inc., the generic pharmaceutical division of Novartis, where she served as Vice President and General Counsel from 2008 to 2011. Prior to Sandoz, she served as Senior Vice President, General Counsel and Secretary for Adolor Corporation, a publicly traded biopharmaceutical company from 2002 to 2008. Martha began her legal career with the law firm of Morgan, Lewis & Bockius. She received her J.D. from the University of Pennsylvania School of Law and her Bachelor of Business Administration from the University of Massachusetts.
Executive Vice President and Chief Operating Officer
Mr. Truitt joined Achillion in January 2009 from Viropharma, Inc. following its acquisition of Lev Pharmaceuticals. At Lev, Mr. Truitt was most recently Vice President of Business Development and Product Strategy and led the build out of the commercial team and infrastructure in preparation for product launch. Mr. Truitt joined Lev from Johnson & Johnson, where he was Vice President of Sales and Operations and directed commercial operations and had P&L responsibility for sales, operations and national accounts at the company’s OraPharma subsidiary. Mr. Truitt holds a BS degree in Marketing from LaSalle University, Philadelphia, and an MBA degree from St. Joseph’s University, Philadelphia.
Dr. Banks joined Achillion in 2013, leading all Chemical Manufacturing & Control (CMC) activities and later taking on additional responsibility to include quality assurance and compliance. Dr. Banks has over 30 years of experience in pharmaceutical research and development. His career has included 27 years with Pfizer in the UK and USA encompassing various functions and increasing levels of responsibility in CMC. Prior to Pfizer, Dr. Banks was head of formulation development within the International Development Centre of Abbott Laboratories, UK. He has a wealth of experience progressing compounds from early development through to successful, global regulatory approvals and commercialization.
He is a pharmacist and graduated from Leicester School of Pharmacy with a BSc (Hons) Pharmacy degree and a PhD in Pharmaceutical Technology. He later earned a MBA with distinction from University of Kent in the UK.
Amy Jennings joined Achillion in January 2016 and serves as Senior Vice President of Regulatory Affairs. She was previously with Sanofi where she was the head of US regulatory for diabetes. Prior to Sanofi, Amy assumed roles of increasing responsibility at Bristol-Myers Squibb within Regulatory over more than 12 years, culminating in her leading U.S. regulatory for CV/Metabolics. Amy earned a BS in Chemistry from the University of Wisconsin-Madison and a Ph.D. in Biochemistry from The Ohio State University. She was a post-doctoral fellow at the Joslin Diabetes Center prior to joining the pharmaceutical industry.
Ms. Nam-Wortman joined Achillion in October 2014 as the Vice President of Human Resources. She brings over 23 years of experience in human resources and strategic change management from Zoetis, Pfizer, Merck, IBM, and Delta Consulting Group. Prior to joining Achillion, she was the Vice President of Talent & Organization Capability for Zoetis (formerly Pfizer Animal Health), Vice President & HR Lead for Pfizer, and has held positions of increasing responsibility while at Pfizer and Merck. Ms. Nam-Wortman has 14 years of experience in the consulting industry focused on strategic and organization change management from Delta Consulting Group and IBM. She received her bachelors in marketing from New York University Stern School of Business and MS in human resources management / organization development from the New School of Social Research.
Ms. Rieger joined Achillion in May 2013 as Senior Director Medical and Regulatory Writing and was promoted to Vice President Portfolio Management in early 2014. She brings over 30 years of drug development experience in several therapeutic areas from Pfizer, Warner-Lambert/Parke-Davis, inVentiv Health Clinical, Boehringer-Ingelheim, Ayerst Laboratories, University of Rochester, and G.D. Searle. While at Pfizer, she was most recently a Portfolio Director for the Inflammation, Dermatology, and Pain therapeutic areas working with the research, development, and commercial business unit heads to implement strategic plans and optimize project delivery. She had previously led a project planning and performance function for clinical studies, had led a development operations team leader function for clinical studies, and had served as the global operations team leader for cardiovascular programs including atorvastatin. She led medical writing departments at Warner-Lambert/Parke Davis and inVentiv Health Clinical and contributed to numerous successful regulatory filings and marketing approvals. Ms. Rieger holds a BS in Biology and Chemistry from Valparaiso University and an MBA from Loyola University Chicago.